PetIQ is a drug manufacturers - specialty & generic business based in the US. PetIQ shares (PETQ) are listed on the NASDAQ and all prices are listed in US Dollars. PetIQ employs 1,121 staff and has a trailing 12-month revenue of around $1.1 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $30.53 |
|---|---|
| 52-week range | $15.09 - $30.68 |
| 50-day moving average | $24.96 |
| 200-day moving average | $20.01 |
| Wall St. target price | $29.67 |
| PE ratio | 82.5676 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.37 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $30.53 from 2024-09-03
| 1 week (2024-08-29) | 0.03% |
|---|---|
| 1 month (2024-08-05) | 47.49% |
| 3 months (2024-06-05) | 43.00% |
| 6 months (2024-03-05) | 84.25% |
| 1 year (2023-09-05) | 67.84% |
|---|---|
| 2 years (2022-09-02) | 251.73% |
| 3 years (2021-09-03) | 13.37% |
| 5 years (2019-09-05) | 3.91% |
Valuing PetIQ stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PetIQ's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
PetIQ's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 83x. In other words, PetIQ shares trade at around 83x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
PetIQ's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5616. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into PetIQ's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
PetIQ's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $101.7 million.
The EBITDA is a measure of a PetIQ's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.1 billion |
|---|---|
| Operating margin TTM | 8.63% |
| Gross profit TTM | $209.7 million |
| Return on assets TTM | 4.86% |
| Return on equity TTM | 5.52% |
| Profit margin | 1.16% |
| Book value | $8.71 |
| Market Capitalization | $913 million |
TTM: trailing 12 months
We're not expecting PetIQ to pay a dividend over the next 12 months.
Over the last 12 months, PetIQ's shares have ranged in value from as little as $15.09 up to $30.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PetIQ's is 1.737. This would suggest that PetIQ's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats. It also provides OTC medications and supplies primarily within the flea and tick control, dog dewormers, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dog and cat treats, oral health solutions, stain and odor treatments, and pet nutritional supplements under the PetArmor®, Rocco & Roxie®, VetIQ®, Minties® and Sentry® brands. It provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PurLuv, Rocco & Roxie, Minties, Heart Shield Plus, and TruProfen brand names.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
Advanced Micro Devices (AMD), Intel Corporation (INTC) and Qualcomm Inc (QCOM) are top stocks like Nvidia. See our full list here.
A deep dive into the highlights and limitations of Frec.
Compare pros, cons, research tools and reviews for these two trading platforms.
What you need to know about investing in the leading indicator for the overall US stock market.
An online REIT with low fees, consistent dividends and a stable portfolio, but a brief track record.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.